Effects of intermittent hypoxia on adipose-derived mesenchymal stem cells in protecting alveolar type II cells from injury.
Lai R., Chen S., Cui J., Liu X., Li Y.
Animal Study, published in PLoS One (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- PLoS One (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41564041
- PMCID
- PMC12822967
- DOI
- 10.1371/journal.pone.0340291
Abstract (original English)
Adipose-derived mesenchymal stem cells (ADSCs) have demonstrated significant therapeutic effects on acute lung injury. Numerous studies have reported that preconditioning ADSCs can enhance their therapeutic efficacy. Currently, there is a lack of research on intermittent hypoxia preconditioning of ADSCs. In this study, we subjected ADSCs to intermittent hypoxic preconditioning, followed by the detection of their expressions of HIF-1α, HGF, VEGF, and IL-10. We also evaluated the therapeutic effects of ADSCs on oxidative stress and cell apoptosis in LPS-induced MLE-12 cells, and compared the outcomes resulting from different types of hypoxic preconditioning. Finally, we concluded that Intermittent hypoxia preconditioning leads to decrease in the secretion of VEGF by ADSCs compared to sustained hypoxia preconditioning; but their therapeutic effects in terms of anti-apoptosis and anti-oxidation are comparable.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.